PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in tissue-targeted AAV gene therapy, today announces the publication of a seminal research ...
Three of 5 (60%) patients on the LoVAS regimen relapsed compared with 2 of 16 (12.5%) on the PEXIVAS regimen. In most cases, relapses occurred early after treatment initiation.
To design safe clinical trials, it is crucial to better understand and predict gene editing outcomes in preclinical studies. Bence György and collaborators have shown that adeno-associated viruses ...
Adeno-associated virus (AAV) has emerged as the most flexible and useful vector for gene therapy. With hundreds of gene therapy trials ongoing, safe and efficient production of AAV is absolutely ...
Several quality attributes (QAs) must be monitored to ensure an effective and safe final product when developing adeno-associated virus (AAV) vectors as drug products. Thermal stability, aggregate ...
Gene therapy adeno-associated viruses (AAVs)—viruses that can be engineered to deliver DNA to target cells—are unlikely to cause cancer-triggering insertions in humans or monkeys and may contribute to ...
AskBio founder R. Jude Samulski talks about the evolution and future of AAV gene therapy following his company’s blockbuster acquisition by Bayer in 2020. R. Jude Samulski, PhD It is rare that a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results